Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohsen, Mona O., Vogel, Monique, Riether, Carsten, Muller, Julius, Salatino, Silvia, Ternette, Nicola, Gomes, Ariane C., Cabral-Miranda, Gustavo, El-Turabi, Aadil, Ruedl, Christiane, Kundig, Thomas M., Dermime, Said, Knuth, Alexander, Speiser, Daniel E., Bachmann, Martin F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532571/
https://www.ncbi.nlm.nih.gov/pubmed/31156619
http://dx.doi.org/10.3389/fimmu.2019.01015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532571/
https://www.ncbi.nlm.nih.gov/pubmed/31156619
http://dx.doi.org/10.3389/fimmu.2019.01015

Ejemplares similares